TY - JOUR
T1 - Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter Trypanosoma brucei
AU - Alghamdi, Ali H.
AU - Munday, Jane C.
AU - Campagnaro, Gustavo Daniel
AU - Gurvic, Dominik
AU - Svensson, Fredrik
AU - Okpara, Chinyere E.
AU - Kumar, Arvind
AU - Quintana, Juan F.
AU - Abril, Maria Esther Martin
AU - Milić, Patrik
AU - Watson, Laura
AU - Paape, Daniel
AU - Settimo, Luca
AU - Dimitriou, Anna
AU - Wielinska, Joanna
AU - Smart, Graeme
AU - Anderson, Laura F.
AU - Woodley, Christopher M.
AU - Kelley, Siu Pui Ying
AU - Ibrahim, Hasan M. S.
AU - Hulpia, Fabian
AU - Al-Salabi, Mohammed I.
AU - Eze, Anthonius A.
AU - Gudin, Simon
AU - Field, Mark
AU - Dardonville, Christophe
AU - Tidwell, Richard R .
AU - Carrington, Mark
AU - O'Neill, Paul M.
AU - Boykin, David W .
AU - Zachariae, Ulrich
AU - de Koning, Harry P.
PY - 2020/9/4
Y1 - 2020/9/4
N2 - Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively selected for increased pore size from a common ancestor aquaporin. We demonstrate that TbAQP2’s unique architecture permits pentamidine permeation through its central pore and show how specific mutations in highly conserved motifs affect drug permeation. Introduction of key TbAQP2 amino acids into TbAQP3 renders the latter permeable to pentamidine. Molecular dynamics demonstrates that permeation by dicationic pentamidine is energetically favourable in TbAQP2, driven by the membrane potential, although aquaporins are normally strictly impermeable for ionic species. We also identify the structural determinants that make pentamidine a permeant although most other diamidine drugs are excluded. Our results have wide-ranging implications for optimising antitrypanosomal drugs and averting crossresistance. Moreover, these new insights in aquaporin permeation may allow the pharmacological exploitation of other members of this ubiquitous gene family.
AB - Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively selected for increased pore size from a common ancestor aquaporin. We demonstrate that TbAQP2’s unique architecture permits pentamidine permeation through its central pore and show how specific mutations in highly conserved motifs affect drug permeation. Introduction of key TbAQP2 amino acids into TbAQP3 renders the latter permeable to pentamidine. Molecular dynamics demonstrates that permeation by dicationic pentamidine is energetically favourable in TbAQP2, driven by the membrane potential, although aquaporins are normally strictly impermeable for ionic species. We also identify the structural determinants that make pentamidine a permeant although most other diamidine drugs are excluded. Our results have wide-ranging implications for optimising antitrypanosomal drugs and averting crossresistance. Moreover, these new insights in aquaporin permeation may allow the pharmacological exploitation of other members of this ubiquitous gene family.
UR - http://www.scopus.com/inward/record.url?scp=85090297368&partnerID=8YFLogxK
U2 - 10.7554/eLife.56416
DO - 10.7554/eLife.56416
M3 - Article
C2 - 32762841
SN - 2050-084X
VL - 9
JO - eLife
JF - eLife
M1 - e56416
ER -